Insider Trading Alert - WASH, ACAT And SPNC Traded By Insiders - TheStreet

Yesterday, Oct. 26, 2015, 38 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $813.28 to $8,898,804.00.

Highlighted Stocks Traded by Insiders:

Washington Trust Bancorp (WASH) - FREE Research Report

Algiere Dennis L, who is SVP Ch Comp Off/Dir Com Affair at Washington Trust Bancorp, sold 600 shares at $39.99 on Oct. 26, 2015. Following this transaction, the SVP Ch Comp Off/Dir Com Affair owned 8,324 shares meaning that the stake was reduced by 6.72% with the 600-share transaction.

The shares most recently traded at $39.55, down $0.44, or 1.11% since the insider transaction. Historical insider transactions for Washington Trust Bancorp go as follows:

  • 4-Week # shares bought: 150
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 150
  • 12-Week # shares sold: 1,000
  • 24-Week # shares bought: 150
  • 24-Week # shares sold: 12,819

The average volume for Washington Trust Bancorp has been 35,500 shares per day over the past 30 days. Washington Trust Bancorp has a market cap of $672.6 million and is part of the financial sector and banking industry. Shares are down 0.6% year-to-date as of the close of trading on Monday.

Washington Trust Bancorp, Inc. operates as the holding company for The Washington Trust Company that offers various banking and financial products and services to individuals and businesses. The company operates in two segments, Commercial Banking and Wealth Management Services. The stock currently has a dividend yield of 3.41%. The company has a P/E ratio of 15.5. Currently, there are no analysts who rate Washington Trust Bancorp a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on WASH - FREE

TheStreet Quant Ratings

rates Washington Trust Bancorp as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, notable return on equity and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Washington Trust Bancorp Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Arctic Cat (ACAT) - FREE Research Report

Fisher Paul, who is Vice President - Operations at Arctic Cat, bought 6,000 shares at $17.82 on Oct. 26, 2015. Following this transaction, the Vice President - Operations owned 21,724 shares meaning that the stake was boosted by 38.16% with the 6,000-share transaction.

Crocker Tracy Jerry, who is VP/GM - ATV Division at Arctic Cat, bought 400 shares at $17.72 on Oct. 26, 2015. Following this transaction, the VP/GM - ATV Division owned 10,695 shares meaning that the stake was boosted by 3.89% with the 400-share transaction.

Williamson Greg, who is Chief Marketing Officer at Arctic Cat, bought 2,800 shares at $16.75 on Oct. 26, 2015. Following this transaction, the Chief Marketing Officer owned 11,432 shares meaning that the stake was boosted by 32.44% with the 2,800-share transaction.

The shares most recently traded at $19.76, up $3.01, or 15.23% since the insider transaction. Historical insider transactions for Arctic Cat go as follows:

  • 4-Week # shares bought: 13,000
  • 4-Week # shares sold: 6,669
  • 12-Week # shares bought: 13,000
  • 12-Week # shares sold: 6,669
  • 24-Week # shares bought: 13,000
  • 24-Week # shares sold: 6,669

The average volume for Arctic Cat has been 195,600 shares per day over the past 30 days. Arctic Cat has a market cap of $258.4 million and is part of the consumer goods sector and automotive industry. Shares are down 43.94% year-to-date as of the close of trading on Monday.

Arctic Cat Inc. designs, engineers, manufactures, and markets snowmobiles and all-terrain vehicles (ATVs), and recreational off-highway vehicles under the Arctic Cat brand name. It also provides related parts, garments, and accessories. The stock currently has a dividend yield of 2.51%. The company has a P/E ratio of 663.3. Currently, there are 3 analysts who rate Arctic Cat a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACAT - FREE

TheStreet Quant Ratings

rates Arctic Cat as a

hold

. Among the primary strengths of the company is its solid financial position based on a variety of debt and liquidity measures that we have evaluated. At the same time, however, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full

Arctic Cat Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Spectranetics (SPNC) - FREE Research Report

Fletcher R John, who is Director at Spectranetics, bought 8,000 shares at $12.41 on Oct. 26, 2015. Following this transaction, the Director owned 121,728 shares meaning that the stake was boosted by 7.03% with the 8,000-share transaction.

The shares most recently traded at $12.51, up $0.10, or 0.78% since the insider transaction. Historical insider transactions for Spectranetics go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 46,000
  • 24-Week # shares sold: 5,000

The average volume for Spectranetics has been 894,600 shares per day over the past 30 days. Spectranetics has a market cap of $539.3 million and is part of the health care sector and health services industry. Shares are down 63.3% year-to-date as of the close of trading on Monday.

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Currently, there are 9 analysts who rate Spectranetics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPNC - FREE

TheStreet Quant Ratings

rates Spectranetics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, feeble growth in its earnings per share, generally high debt management risk and generally disappointing historical performance in the stock itself. Get the full

Spectranetics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.